Lung Diseases, Interstitial Clinical Trials

14 recruiting

Lung Diseases, Interstitial Trials at a Glance

14 actively recruiting trials for lung diseases, interstitial are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Not Applicable with 4 trials, with the heaviest enrollment activity in Mexico City, Ancona, and Angers. Lead sponsors running lung diseases, interstitial studies include Boehringer Ingelheim, GlaxoSmithKline, and Albert Einstein College of Medicine.

Browse lung diseases, interstitial trials by phase

Treatments under study

About Lung Diseases, Interstitial Clinical Trials

Looking for clinical trials for Lung Diseases, Interstitial? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lung Diseases, Interstitial trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lung Diseases, Interstitial clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Not Applicable

NIVATS Versus IGAVATS: a Pilot Trial Addressing Biopsy Quality in Undetermined Interstitial Lung Diseases

Lung Diseases, Interstitial
University Hospital, Montpellier24 enrolled1 locationNCT05722340
Recruiting
Phase 3

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

Lung Diseases, Interstitial
GlaxoSmithKline440 enrolled131 locationsNCT06572384
Recruiting
Phase 2

H01 in Adults With Interstitial Lung Disease (The SOLIS Study)

Interstitial Lung DiseaseLung Diseases, InterstitialIdiopathic Pulmonary Fibrosis
National Institute of Environmental Health Sciences (NIEHS)37 enrolled1 locationNCT06325696
Recruiting
Phase 1

Nebulized Human Amniotic Fluid in Patients With Interstitial Lung Disease

Lung Diseases, Interstitial
Maule Stem Cell Research Institute, Inc.50 enrolled1 locationNCT07372989
Recruiting

Database for Interstitial Lung Disease

Lung Diseases, Interstitial
Medical University of Graz412 enrolled1 locationNCT04707781
Recruiting

Cough Capture as a Portal Into the Lung

Lung CancerLung DiseasesLung Diseases, Obstructive+2 more
Albert Einstein College of Medicine2,000 enrolled1 locationNCT05854563
Recruiting

Dorothy P. and Richard P. Simmons Center for ILD Research Registry

Lung Diseases, Interstitial
University of Pittsburgh5,000 enrolled1 locationNCT00258583
Recruiting

Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) Epidemiology Non-interventional Study (NIS)

Lung Diseases, Interstitial
Boehringer Ingelheim312 enrolled1 locationNCT05819385
Recruiting
Not Applicable

Comparison of PR Efficiency in Home-based With Hospital-based PR in Bronchiectasis

Lung DiseasesLung Diseases, InterstitialBronchiectasis+1 more
Istanbul Medipol University Hospital50 enrolled1 locationNCT03561818
Recruiting
Not Applicable

A Randomised Clinical Trial of a Digital Self-management Package for People With Interstitial Lung Disease

Lung Diseases, InterstitialPulmonary Fibrosis
University of Sydney400 enrolled4 locationsNCT06122233
Recruiting
Phase 2Phase 3

Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases

Lung Diseases, Interstitial
R-Pharm International, LLC138 enrolled33 locationsNCT06440746
Recruiting

A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC

NSCLCImmunotherapyLung Diseases, Interstitial
Universitaire Ziekenhuizen KU Leuven70 enrolled1 locationNCT04807114
Recruiting
Not Applicable

Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation

Lung Diseases, Interstitial
University of South Florida70 enrolled1 locationNCT05866198
Recruiting

European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank

Lung Diseases, InterstitialPulmonary FibrosisChild+3 more
Matthias Griese1,000 enrolled3 locationsNCT02852928